Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Proteogenomic study may lead to more effective treatments for head and neck squamous cell carcinoma

Proteogenomic study may lead to more effective treatments for head and neck squamous cell carcinoma

Triple drug combination keeps people with metastatic colon cancer disease free for longer time

Triple drug combination keeps people with metastatic colon cancer disease free for longer time